心脏放射治疗暂时改变左心室的电特性,并诱导心肌细胞特异性心脏基质变化,导致心力衰竭
Felix Mehrhof1, Judith Hüttemeister2,3, Radu Tanacli2,3
1Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin Berlin, Berlin, Germany.
概括
立体心脏放射性废除 (cRA) 可能会改变心脏导电心力衰竭患者心室性心力衰竭. 这项研究发现,在cRA后,局部激活时间和通道表达的短暂变化.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 通过心脏切除术 (Cardiac Ablation) 进行心脏切除.
背景情况:
- 立体心脏放射性废除 (cRA) 正在研究用于治疗心力衰竭患者的心室性心力衰竭 (VT).
- 对cRA对人类心脏组织的影响的确切机制尚未完全理解.
- 之前的动物研究表明cRA会影响局部心脏导电.
研究的目的:
- 研究cRA对心脏衰竭和静脉瘤患者的心肌特性的体内和体外影响.
- 阐明cRA治疗潜力的基础细胞和分子机制.
主要方法:
- 在患有左心室辅助器件和复发性静脉瘤的患者中,在cRA之前和之后进行了高密度的3D电解剖绘制.
- 来自辐射和边界区域的肌肉组织样本进行了分子变化和线粒体密度分析.
- 在体外研究中评估了这些区域的分离心肌细胞.
主要成果:
- 心脏放射除改变了局部电压,并在被辐射的隔膜中显著缩短了局部激活时间,这种效应是可逆的.
- 在照射区域观察到电压依赖通道的增加表达.
- 与边界区域相比,在被辐射的心肌组织中,线粒体密度下降.
结论:
- 这些发现表明,cRA诱导心脏导电的短暂变化,可能是通过结构和功能细胞变化.
- 这些短暂的变化可能有助于cRA在治疗心室动脉障碍时的治疗效果.
- 进一步的研究是有必要的,以充分了解长期影响和优化cRA协议.
更多相关视频
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
28.6K
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
2.9K
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
416
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416
01:29Cardiomyopathy V: Interprofessional Care
343
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
472
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
472
01:22Heart Failure VI: Adjunct Therapies
263
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K